Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

NICE published a draft guideline on wireless device for treating people with overactive bladder

21 Feb 2020

Axonics sacral neuromodulation would be an option for people with symptoms of the overactive bladder who have not responded to conservative treatments or drug therapy. The Axonics device could save the NHS around £6,200 per patient if the device lasts more than six years.

The following recommendations were provided in the draft guideline:

  • Evidence supports the case for adopting Axonics sacral neuromodulation (SNM) system for treating refractory overactive bladder in the NHS. Axonics SNM system improves symptoms and quality of life. It also has a longer battery life than the non-rechargeable system used in NHS clinical practice
  • Axonics SNM system should be considered as an option for people with refractory overactive bladder, that is, when conservative treatment or drug therapy has not worked, in line with NICE's guidelines on urinary incontinence and pelvic organ prolapse and lower urinary tract symptoms. Axonics SNM system is small and does not need to be removed for MRI, so it may be useful for people with a low body mass index (BMI) or when a full-body MRI is likely
  • Cost modeling suggests that over 15 years, the Axonics SNM system is cost-saving compared with the non-rechargeable system by about £6,200 per person. Cost savings are estimated to begin six years after implant. This is because the device needs to be replaced less frequently than the non-rechargeable system, assuming Axonics has a life span of at least 15 years

Consultations are open to the stakeholders until March 13, 2020.The expected publication date of the final guideline is June 1, 2020.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.